Fulcrum Therapeutics agrees to sell early-stage HbF assets for about $7 million
FULC•Fulcrum Therapeutics agreed to sell its early-stage fetal hemoglobin assets for approximately $7 million in cash. The sale is contingent on completion of its proposed merger with Slate Medicines or necessary approvals if that agreement ends.
1. Asset sale terms
Fulcrum Therapeutics and Slate Medicines agreed on November 7, 2026, to sell Fulcrum’s early-stage fetal hemoglobin assets for approximately $7 million in cash to an unaffiliated pharmaceutical company. Closing depends on completion of the proposed Slate merger under an August 16, 2026, agreement, or necessary approvals if that agreement terminates.
2. Expected proceeds
The proceeds are expected to enter escrow before the merger closes, count toward merger net cash and increase the expected cash dividend.
